Humacyte Appoints Key Nephrologists as Advisors to Prepare for Planned Commercialization of the ATEV in Dialysis Access
Humacyte, Inc. announced the appointment of two prominent nephrologists, Dr. Robert J. Kossmann and Dr. Prabir Roy-Chaudhury, as advisors to support the commercialization of its acellular tissue engineered vessel (ATEV) for hemodialysis access. The appointments follow positive Phase 3 V012 study results in women and plans to file a supplemental Biologic License Application with the FDA.
Read original at globenewswire-inc